Delivery Order SPE2DB22D3401-SPE2DB25FT6AU
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at approximately $37,038 to AmerisourceBergen Drug Corp on September 4, 2025, for the supply of Enbrel 50 mg/ml SureClick auto-injector pens. This is a firm fixed price, competitively awarded contract with no set-aside designation, with ultimate completion scheduled for September 5, 2025. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a...
- The Defense Logistics Agency awarded a $54,357.69 firm fixed price delivery order to AmerisourceBergen Drug Corp on September 8, 2025, for Enbrel 50 mg/mL SureClick auto-injector pens. This non-set-aside contract is a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. The product will be performed at AmerisourceBergen's corporate headquarters location in Conshohocken,...
- The Defense Logistics Agency awarded a $9,749.84 firm fixed price delivery order to AmerisourceBergen Drug Corp on August 28, 2025, for the supply of Enbrel 50 mg/mL SureClick auto-injector pens. This non-set-aside delivery order represents a single line item procurement from AmerisourceBergen's existing indefinite delivery contract with DLA Troop Support Medical. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, with an ultimate...
- The Defense Logistics Agency awarded a $14,002.71 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Enbrel 50 mg/ml SureClick auto-injector pens, with an ultimate completion date of August 8, 2025. This non-set-aside award was issued on August 8, 2025, and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp is a major pharmaceutical distributor and critical federal medical supply vendor that serves military...
- The Defense Logistics Agency awarded a delivery order valued at $36,469.66 to AmerisourceBergen Drug Corp for the supply of Enbrel 50 mg/mL SureClick auto-injectors. The contract, awarded on September 8, 2025, with an ultimate completion date of September 9, 2025, represents a firm fixed price delivery order with no set-aside designation. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving as a critical vendor for federal...
- The Defense Logistics Agency awarded a $13,844.92 delivery order to AmerisourceBergen Drug Corp for the supply of Enbrel 50 mg/ml SureClick auto-injectors. This non-set-aside, competitively awarded contract utilized firm fixed pricing and was completed on July 24, 2025. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a continuation of the company's established role as a critical pharmaceutical supplier to the...
- The Defense Logistics Agency awarded a delivery order valued at $10,226.52 to AmerisourceBergen Drug Corp for the supply of Enbrel 50 mg/mL SureClick auto-injector pens. This firm fixed-price delivery order was competitively awarded without set-aside designation and is scheduled for completion by July 21, 2025. The product will be delivered to AmerisourceBergen's facility in Conshohocken, Pennsylvania, where the company maintains its corporate headquarters and pharmaceutical distribution...
- The Defense Logistics Agency awarded a $65,024.56 firm fixed price delivery order to AmerisourceBergen Drug Corp for ENBREL 50 mg/ml SureClick autoinjector pharmaceutical supplies on September 2, 2025, with an ultimate completion date of September 3, 2025. The contract involves no set-aside designation and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC)...
- The Defense Logistics Agency awarded a delivery order valued at $13,729.56 to AmerisourceBergen Drug Corp for the supply of Enbrel 50 mg/mL SureClick auto-injectors. The contract utilizes firm fixed-price pricing with no set-aside designation, indicating competitive award. The delivery order is set to be completed by July 31, 2025, and will be fulfilled at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a single transaction within a...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $19,183.90 to AmerisourceBergen Drug Corp for the supply of Enbrel 50 mg/ml SureClick auto-injectors. This firm fixed-price delivery order, issued on August 5, 2025, with an ultimate completion date of August 6, 2025, represents a competitively awarded contract with no set-aside designation. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. As a major...
- SPE2DB22D3401Indefinite Delivery Contract
- SPE2DB22D3401-SPE2DB25FT6AUDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $64,327.41 to AmerisourceBergen Drug Corp for the supply of Enbrel 50 mg/ml SureClick auto-injector pens. This firm fixed-price delivery order, issued on September 8, 2025, with completion targeted for September 9, 2025, was competitively awarded without set-aside restrictions. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as the performing location for this pharmaceutical supply contract, leveraging its extensive capabilities as a major healthcare solutions provider and critical vendor for federal medical procurement. This delivery order is executed under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. This prime contract vehicle enables the company to supply pharmaceutical products and medical supplies to support military healthcare programs globally. Enbrel is a specialized immunosuppressant medication used to treat autoimmune conditions, reflecting the company's role in delivering specialty pharmaceutical products across multiple therapeutic domains to support the Defense Health Agency and other federal healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $64.3k | 9/8/25 |